DAPTOMYCIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C72H101N17O26
Molecular Weight	1620.6735
Optical Activity	UNSPECIFIED
Defined Stereocenters	13 / 13
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]3[C@@H](C)OC(=O)[C@H](CC(=O)C4=CC=CC=C4N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC3=O)[C@H](C)CC(O)=O

InChI

InChIKey=DOAKLVKFURWEDJ-QCMAZARJSA-N

InChI=1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45-,46+,47+,48+,49+,50-,60+,61+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C72H101N17O26
Molecular Weight	1620.6735
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	13 / 13
E/Z Centers	2
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021572s033lbl.pdf
Curator's Comment: description was created based on several sources, including: https://www.drugbank.ca/drugs/DB00080

Daptomycin is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms. Daptomycin has a distinct mechanism of action, disrupting multiple aspects of bacterial cell membrane function. It inserts into the cell membrane in a phosphatidylglycerol-dependent fashion, where it then aggregates. The aggregation of daptomycin alters the curvature of the membrane, which creates holes that leak ions. This causes rapid depolarization, resulting in a loss of membrane potential leading to inhibition of protein, DNA, and RNA synthesis, which results in bacterial cell death. Daptomycin is bactericidal against Gram-positive bacteria only. It has proven in vitro activity against enterococci (including glycopeptide-resistant enterococci (GRE)), staphylococci (including methicillin-resistant Staphylococcus aureus), streptococci, corynebacteria and stationary-phase Borrelia burgdorferi persisters.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Staphylococcus aureus 70 Target ID: CHEMBL352 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021572s038lbl.pdf	Binding Agent 1076
Staphylococcus 2 Target ID: CHEMBL612624 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20176900	Binding Agent 1076

Conditions

Condition	Modality	Targets	Highest Phase	Product
Complicated skin and skin structure infections 11 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021572s038lbl.pdf	Curative		Approved 8583	CUBICIN Approved Use CUBICIN® is indicated for the treatment of the infections listed below. CUBICIN is a lipopeptide antibacterial indicated for the treatment of: Complicated skin and skin structure infections (cSSSI) (1.1) Staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis (1.2) CUBICIN is not indicated for the treatment of pneumonia. (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of CUBICIN and other antibacterial drugs, CUBICIN should be used to treat infections that are proven or strongly suspected to be caused by bacteria. 1.1 Complicated Skin and Skin Structure Infections Complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only). 1.2 Staphylococcus aureus Bloodstream Infections (Bacteremia), Including Those with Right-Sided Infective Endocarditis, Caused by Methicillin-Susceptible and Methicillin-Resistant Isolates Staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates. 1.3 Limitations of Use CUBICIN is not indicated for the treatment of pneumonia. CUBICIN is not indicated for the treatment of left-sided infective endocarditis due to S. aureus. The clinical trial of CUBICIN in patients with S. aureus bloodstream infections included limited data from patients with left-sided infective endocarditis; outcomes in these patients were poor [see Clinical Trials (14.2) Launch Date 2003
Staphylococcus aureus bloodstream infections 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021572s038lbl.pdf	Curative		Approved 8583	CUBICIN Approved Use CUBICIN® is indicated for the treatment of the infections listed below. CUBICIN is a lipopeptide antibacterial indicated for the treatment of: Complicated skin and skin structure infections (cSSSI) (1.1) Staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis (1.2) CUBICIN is not indicated for the treatment of pneumonia. (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of CUBICIN and other antibacterial drugs, CUBICIN should be used to treat infections that are proven or strongly suspected to be caused by bacteria. 1.1 Complicated Skin and Skin Structure Infections Complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only). 1.2 Staphylococcus aureus Bloodstream Infections (Bacteremia), Including Those with Right-Sided Infective Endocarditis, Caused by Methicillin-Susceptible and Methicillin-Resistant Isolates Staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates. 1.3 Limitations of Use CUBICIN is not indicated for the treatment of pneumonia. CUBICIN is not indicated for the treatment of left-sided infective endocarditis due to S. aureus. The clinical trial of CUBICIN in patients with S. aureus bloodstream infections included limited data from patients with left-sided infective endocarditis; outcomes in these patients were poor [see Clinical Trials (14.2) Launch Date 2003

C_max

Value	Dose	Analyte	Population
59.1 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00428844	6 mg/kg 1 times / day steady, intravenous dose: 6 mg/kg route of administration: intravenous experiment type: steady co-administered:	DAPTOMYCIN plasma	Homo sapiens population: unhealthy age: Adults sex: F+M food status:
92.3 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00428844	8 mg/kg 1 times / day steady, intravenous dose: 8 mg/kg route of administration: intravenous experiment type: steady co-administered:	DAPTOMYCIN plasma	Homo sapiens population: unhealthy age: Adults sex: F+M food status:
57.8 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	4 mg/kg 1 times / day steady-state, intravenous dose: 4 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
93.9 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	6 mg/kg 1 times / day steady-state, intravenous dose: 6 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
123.3 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	8 mg/kg 1 times / day steady-state, intravenous dose: 8 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
141.1 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	10 mg/kg 1 times / day steady-state, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
183.7 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	12 mg/kg 1 times / day steady-state, intravenous dose: 12 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
499 ug*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00428844	6 mg/kg 1 times / day steady, intravenous dose: 6 mg/kg route of administration: intravenous experiment type: steady co-administered:	DAPTOMYCIN plasma	Homo sapiens population: unhealthy age: Adults sex: F+M food status:
821 ug*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00428844	8 mg/kg 1 times / day steady, intravenous dose: 8 mg/kg route of administration: intravenous experiment type: steady co-administered:	DAPTOMYCIN plasma	Homo sapiens population: unhealthy age: Adults sex: F+M food status:
494 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	4 mg/kg 1 times / day steady-state, intravenous dose: 4 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
632 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	6 mg/kg 1 times / day steady-state, intravenous dose: 6 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
858 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	8 mg/kg 1 times / day steady-state, intravenous dose: 8 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1039 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	10 mg/kg 1 times / day steady-state, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1277 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	12 mg/kg 1 times / day steady-state, intravenous dose: 12 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
8.1 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	4 mg/kg 1 times / day steady-state, intravenous dose: 4 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.9 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	6 mg/kg 1 times / day steady-state, intravenous dose: 6 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
8.3 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	8 mg/kg 1 times / day steady-state, intravenous dose: 8 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.9 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	10 mg/kg 1 times / day steady-state, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.7 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	12 mg/kg 1 times / day steady-state, intravenous dose: 12 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
8.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	4 mg/kg 1 times / day steady-state, intravenous dose: 4 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
10 mg/kg single, intravenous Highest studied dose Dose: 10 mg/kg Route: intravenous Route: single Dose: 10 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/21317681/	unhealthy, 2 - 6 years Health Status: unhealthy Age Group: 2 - 6 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/21317681/	Sources: https://pubmed.ncbi.nlm.nih.gov/21317681/
6 mg/kg 1 times / day steady, intravenous Recommended Dose: 6 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 6 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/	unhealthy, 21 - 87 years Health Status: unhealthy Age Group: 21 - 87 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/	Disc. AE: Creatine kinase increased, Renal impairment... AEs leading to discontinuation/dose reduction: Creatine kinase increased (3 patients) Renal impairment (1 patient) Death (18 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/
6 mg/kg single, intravenous Recommended Dose: 6 mg/kg Route: intravenous Route: single Dose: 6 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/25361023/	unhealthy, 3–24 Months Health Status: unhealthy Age Group: 3–24 Months Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25361023/	Sources: https://pubmed.ncbi.nlm.nih.gov/25361023/
10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 60.8 - 80.8 years Health Status: unhealthy Age Group: 60.8 - 80.8 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	Disc. AE: Cardiac failure, Hypocalcemia... AEs leading to discontinuation/dose reduction: Cardiac failure (4 patients) Hypocalcemia (grade 4, 1 patient) Acute renal failure (1 patient) Acute liver injury (1 patient) Gastrointestinal bleeding (1 patient) Nausea and vomiting (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/
10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 62 - 80 years Health Status: unhealthy Age Group: 62 - 80 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	Disc. AE: Acute renal failure, Respiratory failure... AEs leading to discontinuation/dose reduction: Acute renal failure (1 patient) Respiratory failure (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/

AEs

AE	Significance	Dose	Population
Renal impairment	1 patient Disc. AE	6 mg/kg 1 times / day steady, intravenous Recommended Dose: 6 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 6 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/	unhealthy, 21 - 87 years Health Status: unhealthy Age Group: 21 - 87 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/
Death	18 patients Disc. AE	6 mg/kg 1 times / day steady, intravenous Recommended Dose: 6 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 6 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/	unhealthy, 21 - 87 years Health Status: unhealthy Age Group: 21 - 87 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/
Creatine kinase increased	3 patients Disc. AE	6 mg/kg 1 times / day steady, intravenous Recommended Dose: 6 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 6 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/	unhealthy, 21 - 87 years Health Status: unhealthy Age Group: 21 - 87 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/
Acute liver injury	1 patient Disc. AE	10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 60.8 - 80.8 years Health Status: unhealthy Age Group: 60.8 - 80.8 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/
Acute renal failure	1 patient Disc. AE	10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 60.8 - 80.8 years Health Status: unhealthy Age Group: 60.8 - 80.8 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/
Gastrointestinal bleeding	1 patient Disc. AE	10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 60.8 - 80.8 years Health Status: unhealthy Age Group: 60.8 - 80.8 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/
Nausea and vomiting	2 patients Disc. AE	10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 60.8 - 80.8 years Health Status: unhealthy Age Group: 60.8 - 80.8 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/
Cardiac failure	4 patients Disc. AE	10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 60.8 - 80.8 years Health Status: unhealthy Age Group: 60.8 - 80.8 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/
Hypocalcemia	grade 4, 1 patient Disc. AE	10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 60.8 - 80.8 years Health Status: unhealthy Age Group: 60.8 - 80.8 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/
Acute renal failure	1 patient Disc. AE	10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 62 - 80 years Health Status: unhealthy Age Group: 62 - 80 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/
Respiratory failure	1 patient Disc. AE	10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 62 - 80 years Health Status: unhealthy Age Group: 62 - 80 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 inducer 1087	inhibitor 2438 inducer 440	inhibitor 2507 inducer 109	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2A6 879 CYP2C19 2057 CYP2E1 1060	P-gp 2052	CYP1A2 832 CYP2A6 86 CYP2C19 329 CYP2E1 131

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2A6 911	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2C19 2141	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2C9 2497	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2D6 2546	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2E1 1146	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2E1 1146	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP3A4 2633	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://academic.oup.com/jac/article/70/1/307/2911350	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_Pharmr.pdf#page=9 Page: 9.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:600103	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:600103
ChemicalBook	CB8855073	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8855073
eMolecules	11312095	https://www.emolecules.com/cgi-bin/more?vid=11312095
MolPort	MolPort-003-846-138	https://www.molport.com/shop/molecule-link/MolPort-003-846-138

PubMed

Title	Date	PubMed
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.	2015-05-18	25811541
Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.	2011-01	20956587
Treatment of meningitis caused by vancomycin-resistant Enterococcus faecium: high-dose and combination daptomycin therapy.	2010-12	21119097
Cerebrospinal fluid penetration of high-dose daptomycin in suspected Staphylococcus aureus meningitis.	2010-11	20959502
Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008).	2010-11	20805395
Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect").	2010-08	20547804
Successful medical treatment of bioprosthetic pulmonary valve endocarditis caused by methicillin-resistant Staphylococcus aureus.	2010-05	20063157
Use of daptomycin in a pregnant patient with Staphylococcus aureus endocarditis.	2010-04	20197474
Daptomycin for methicillin-resistant Staphylococcus epidermidis native-valve endocarditis: a case report.	2010-02-18	20167084
Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.	2009-10	19620326
Successful salvage therapy with daptomycin after linezolid and vancomycin failure in a liver transplant recipient with methicillin-resistant Staphylococcus aureus endocarditis.	2009-08	19497075
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains.	2009-04	19188393
Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06.	2008-11	18819981
Community-associated methicillin-resistant Staphylococcus aureus pyomyositis complicated by compartment syndrome in an immunocompetent young woman.	2008-07	18606349
Daptomycin-induced acute renal and hepatic toxicity without rhabdomyolysis.	2008-05	18381844
Successful treatment of vancomycin-resistant Enterococcus faecium pyelonephritis with daptomycin during pregnancy.	2008-05	18349306
[New anti-Gram+antibiotics: which role in infective endocarditis?].	2008-04	18395180
Therapy-refractory Panton Valentine Leukocidin-positive community-acquired methicillin-sensitive Staphylococcus aureus sepsis with progressive metastatic soft tissue infection: a case report.	2007-12-03	18053175
Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster.	2007-11-15	17968832
Community-phenotype-methicillin-resistant Staphylococcus aureus infections: a retrospective chart review of outcomes after treatment with daptomycin.	2007-11	18158084
Daptomycin in the treatment of patients with infective endocarditis: experience from a registry.	2007-10	17904948
Daptomycin in the treatment of bacteremia.	2007-10	17904947
Infective endocarditis caused by USA300 methicillin-resistant Staphylococcus aureus (MRSA).	2007-07	17428640
Eosinophilic pneumonia induced by daptomycin.	2007-04	17207858
Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers.	2006-10	17005801
Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.	2006-08	16787952
Rhabdomyolysis and acute renal failure in a patient treated with daptomycin.	2006-03	16410267
Successful treatment of Corynebacterium striatum endocarditis with daptomycin plus rifampin.	2005-10	16144879
Severe myopathy and possible hepatotoxicity related to daptomycin.	2005-04	15743894
Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin.	2005-01-14	15647736
Muscle pain associated with daptomycin.	2004-11	15367725
Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.	2003-05	12709345
Effects of daptomycin and vancomycin on tobramycin nephrotoxicity in rats.	1990-01	2158272
Influence of daptomycin on staphylococcal abscesses and experimental tobramycin nephrotoxicity.	1989-08	2552905

Patents

Sample Use Guides

In Vivo Use Guide

4 mg/kg once every 24 hours (every 48 hours if creatinine clearance <30 mL/min) 6 mg/kg once every 24 hours (every 48 hours if creatinine clearance <30 mL/min)

Route of Administration: Intravenous

In Vitro Use Guide

In vitro activities of daptomycin was studied against more than 100 strains each of Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes. For 392 of 421 strains (93%), daptomycin was inhibitory at <1 g/ml,

Substance Class	Chemical Created by `admin` on `Wed Apr 02 08:41:25 GMT 2025` Edited by `admin` on `Wed Apr 02 08:41:25 GMT 2025`
Record UNII	NWQ5N31VKK
Record Status	`FAILED`
Record Version

Download

Name

Type

Language

CIDECIN

Preferred Name

English

DAPTOMYCIN

Official Name

English

DAPTOMYCIN [MI]

Common Name

English

LY-146032

Code

English

CUBICIN

Brand Name

English

3.4,1.13-anhydro[N-decanoyl-L-tryptophyl-D-asparaginyl-L-?-aspartyl-L-threonylglycyl- L-ornithyl-L-?-aspartyl-D -alanyl-L-?-aspartylglycyl-D -seryl-(3R)-3-methyl-L-?-glutamyl-(2S)-2-amino-4-(2-aminophenyl)-4-oxobutanoic acid]

Systematic Name

English

DAPTOMYCIN [MART.]

Common Name

English

DAPTOMYCIN [ORANGE BOOK]

Common Name

English

daptomycin [INN]

Common Name

English

DAPZURA RT

Brand Name

English

LY 146032

Code

English

DAPTOMYCIN [USAN]

Common Name

English

DAPTOMYCIN [EMA EPAR]

Common Name

English

LY-164032

Code

English

N-decanoyl-L-tryptophyl-D-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L- aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L- alanine ?1-lactone

Systematic Name

English

DAPTOMYCIN [JAN]

Common Name

English

Daptomycin [WHO-DD]

Common Name

English

DAPCIN

Brand Name

English

DAPTOMYCIN [VANDF]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175509